SynthesisSchizophrenia bulletin2015
The promise of biological markers for treatment response in first-episode psychosis: a systematic review.
Synthesis in Schizophrenia bulletin, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03309475 (Mindfulness-based Social Cognition Group Training), which is not on this map. Cited by 53 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mindfulness-based Social Cognition Group Training (SocialMIND) Versus Psychoeducational Multicomponent Intervention in Patients With a First Episode of Psychosis (AGES-Mind Study): A Randomized Controlled Trial
Who cites it
53 citing papers in PubMed, 3 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- fMRI connectivity as a biomarker of antipsychotic treatment response: A systematic review.NeuroImage. Clinical · 2023Pooled it
- The Role of Peripheral Inflammation in Clinical Outcome and Brain Imaging Abnormalities in Psychosis: A Systematic Review.Frontiers in psychiatry · 2021Pooled it
- DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder.International journal of molecular sciences · 2018Pooled it
- Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study.Translational psychiatry · 2019Trial
- The Danish Region Midt Schizophrenia Cohort - Representative, long-term follow-up of first-episode schizophrenia spectrum disorder.Acta neuropsychiatrica · 2026Article
- Article
- Correlation networks of blood proteins in the neuroimmunology of schizophrenia-replication and extension.Translational psychiatry · 2026Article
- Exploration of Early-Treatment-Associated Changes in Metabolic and Inflammatory Biomarkers in First-Episode Psychosis in Italian Patients.International journal of molecular sciences · 2026Article
- Using blood methylomes to predict response to amisulpride in the first-episode psychosis in the OPTiMiSE cohort.Translational psychiatry · 2025Article
- The Potential of Hair Matrix for Biomarker Analysis in Schizophrenia.International journal of molecular sciences · 2025Review
- The Role of Neuroglia in the Development and Progression of Schizophrenia.Biomolecules · 2024Review
- Diagnostic Stability in Psychiatric Patients From Hospital Admission to Discharge: A 10-Year Retrospective Study.Psychiatry investigation · 2023Article
- A machine learning approach on whole blood immunomarkers to identify an inflammation-associated psychosis onset subgroup.Molecular psychiatry · 2023Article
- Metabolic Syndrome in Adults Receiving Clozapine; The Need for Pharmacist Support.Pharmacy (Basel, Switzerland) · 2023Article
- Macroscale EEG characteristics in antipsychotic-naïve patients with first-episode psychosis and healthy controls.Schizophrenia (Heidelberg, Germany) · 2023Article
- Frontal lobe fALFF measured from resting-state fMRI as a prognostic biomarker in first-episode psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- DNA methylation levels of RELN promoter region in ultra-high risk, first episode and chronic schizophrenia cohorts of schizophrenia.Schizophrenia (Heidelberg, Germany) · 2022Article
- Role and Perspectives of Inflammation and C-Reactive Protein (CRP) in Psychosis: An Economic and Widespread Tool for Assessing the Disease.International journal of molecular sciences · 2021Review
- Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia.Biomolecules · 2021Article
- MMP9/RAGE pathway overactivation mediates redox dysregulation and neuroinflammation, leading to inhibitory/excitatory imbalance: a reverse translation study in schizophrenia patients.Molecular psychiatry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 7 countries.
Funding
Abstract
Successful treatment of first-episode psychosis is one of the major factors that impacts long-term prognosis. Currently, there are no satisfactory biological markers (biomarkers) to predict which patients with a first-episode psychosis will respond to which treatment. In addition, a non-negligible rate of patients does not respond to any treatment or may develop side effects that affect adherence to the treatments as well as negatively impact physical health. Thus, there clearly is a pressing need for defining biomarkers that may be helpful to predict response to treatment and sensitivity to side effects in first-episode psychosis. The present systematic review provides (1) trials that assessed biological markers associated with antipsychotic response or side effects in first-episode psychosis and (2) potential biomarkers associated with biological disturbances that may guide the choice of conventional treatments or the prescription of innovative treatments. Trials including first-episode psychoses are few in number. Most of the available data focused on pharmacogenetics markers with so far only preliminary results. To date, these studies yielded-beside markers for metabolism of antipsychotics-no or only a few biomarkers for response or side effects, none of which have been implemented in daily clinical practice. Other biomarkers exploring immunoinflammatory, oxidative, and hormonal disturbances emerged as biomarkers of first-episode psychoses in the last decades, and some of them have been associated with treatment response. In addition to pharmacogenetics, further efforts should focus on the association of emergent biomarkers with conventional treatments or with innovative therapies efficacy, where some preliminary data suggest promising results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.